Recent Posts

Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Inten…

[ad_1] Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Macular Edema Due to Retinal Vein Occlusion: A Real World Analysis of 12,214 Eyes. | IOVS | ARVO Journals https://t.co/4mTZQomaF6 [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ophthopedia: Ophthopedia Update: Suprachoroidal Delivery with the SCS Microi…

[ad_1] RT @ophthopedia: Ophthopedia Update: Suprachoroidal Delivery with the SCS Microinjector™: Characterization of Operational Forces https://t.… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

Lean Six Sigma concepts can reduce waste and enhance patient care. Our paper i…

[ad_1]

Lean Six Sigma concepts can reduce waste and enhance patient care.
Our paper in this month’s OSLI Retina was recently featured.
Evolution of Primary Scleral Buckling Surgery: A Modified Lean Six Sigma Technique to Improve Surgical Efficiency
https://t.co/NalbwxNi7N https://t.co/lIUyalqbpG
[ad_2]

Source by Thomas Ciulla, MD, MBA

Return to main website.

Recently published…Diabetic macular edema, a leading cause of vision loss, is …

[ad_1] Recently published…Diabetic macular edema, a leading cause of vision loss, is treated less intensely and shows worse outcomes than in clinical trials. More effective and longer acting therapies are needed. A Real-World Analysis of 28,658 Patient Eyes… https://t.co/0urP9sJjdl [ad_2] Source by Thomas Ciulla, MD, 

Just published…Lean Six Sigma concepts can reduce waste and enhance patient care…

[ad_1] Just published…Lean Six Sigma concepts can reduce waste and enhance patient care: Evolution of Primary Scleral Buckling Surgery: A Modified Lean Six Sigma Technique to Improve Surgical Efficiency #ophthalmology #retina #surgery #lean #leanhealthcare https://t.co/A3UgEyet97 [ad_2] Source by Thomas Ciulla, MD, MBA Return to main 

RT @RetinaToday: Today’s throwback article is from August 2019 where Thomas A. C…

[ad_1]
RT @RetinaToday: Today’s throwback article is from August 2019 where Thomas A. Ciulla, MD, MBA, took a look at clinical research teams work…
[ad_2]

Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @RetinalPhys: IOP with Suprachoroidal Triamcinolone: How Big a Deal is It? #…

[ad_1] RT @RetinalPhys: IOP with Suprachoroidal Triamcinolone: How Big a Deal is It? https://t.co/5OedaUuzs7 #sponsored https://t.co/5ObWVj4Mtu [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose… via @T…

[ad_1] Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose… https://t.co/YDmBvct5vx via @TrialBulletin [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ophthopedia: Ophthopedia Update: Suprachoroidal triamcinolone acetonide impr…

[ad_1]
RT @ophthopedia: Ophthopedia Update: Suprachoroidal triamcinolone acetonide improves vision in patients with macular edema https://t.co/Zwl
[ad_2]

Source by Thomas Ciulla, MD, MBA

Return to main website.

Very nice commentary, highly relevant to anyone interested in clinical trials: A…

[ad_1] Very nice commentary, highly relevant to anyone interested in clinical trials: Are P Values Enough? https://t.co/jCOeSrkZJy [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.